← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
IRONWOOD PHARMACEUTICALS INC: Revenue declined 15.7% to $296M from $351M. Net income grew 2629.2% to $24.02M from $880K. Free cash flow grew 22.8% to $127M from $103M. Operating margin expanded 676 bps to 33.26%. IRONWOOD PHARMACEUTICALS INC's annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 15.7% to $296M from $351MWatch
- Profitability — Net income grew 2629.2% to $24.02M from $880KOK
- Cash flow — Free cash flow grew 22.8% to $127M from $103MOK
- Margins — Operating margin expanded 676 bps to 33.26%OK
- Accounting — Distress-range screen needs contextWatch
- Insiders — 0 purchases and 20 salesWatch
Business
Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for the technology, inventions and improvements we consider important to our business; defend our patents; preserve the confidentiality of our trade secrets; and operate without infringing the patents and proprietary rights of third parties.
Where the revenue comes from
Fiscal 2025, as IRONWOOD PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Collaborative Arrangements$296.2M
- Collaborative Arrangements Linzess$289.3M
- Royalty$1.7M
- Collaborative Arrangement Collaboration And License Agreements$1.7M
- Collaborative Arrangement Other Agreements$87K
Leadership changes
From IRONWOOD PHARMACEUTICALS INC's own filings, the day they're filed.
- Gregory Martini · Chief Financial Officer · departureeff. 2026-05-15
- Andrew Dreyfus · Directors · departureeff. 2025-11-01
- Gregory Martini · Chief Financial Officer · appointmenteff. 2025-01-27
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about IRONWOOD PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.